Tong Ren Tang's four products get Canada's registration

Tong Ren Tang's four products get Canada's registration

Tong Ren Tang Expands Global Reach with Canadian Product License
Beijing Tong Ren Tang, a leading Chinese herbal medicine company with a 355-year history, has secured a Canadian product license for one of its pharmaceutical formulations, marking a key step in its international expansion. The company announced that its constipation treatment, Shen Ling Bai Zhu San, has received regulatory approval in Canada, enabling broader market access in North America according to company announcement. This development aligns with the company's strategy to standardize traditional Chinese medicine (TCM) products for global markets.

As one of China's oldest TCM brands, Beijing Tong Ren Tang has long been recognized for its heritage in general TCM, tonics, and wellness products. Founded in 1669, the company historically served as the Qing Dynasty's imperial supplier and continues to blend traditional formulations with modern manufacturing as detailed in company profiles. Its recent Canadian approval underscores growing international acceptance of TCM, particularly for conditions like digestive health, where Shen Ling Bai Zhu San is marketed as a natural remedy.

The licensing milestone follows a broader trend of TCM companies seeking global validation. For instance, Shandong Buchang Pharmaceuticals' Danshen Dripping Pills recently underwent FDA clinical trials, demonstrating the sector's push for scientific credibility according to industry analysis. However, regulatory hurdles remain significant, as TCM products must meet stringent international standards for safety, efficacy, and quality control.

In parallel, Beijing Tong Ren Tang has navigated internal restructuring. In late 2025, the company terminated its existing trademark licensing agreement with Tong Ren Tang Holdings and replaced it with a new framework extending through December 2027. The revised terms tie licensing fees to operating revenue, potentially impacting short-term financial obligations but ensuring continued brand usage as reported in press release.

While the Canadian approval is a positive signal for the company's international ambitions, investors should monitor how regulatory, competitive, and operational challenges shape its growth trajectory. With TCM's global market projected to expand, Beijing Tong Ren Tang's ability to balance heritage with innovation will remain critical to its long-term success.